Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2017 Nov 13;17(1):297–305. doi: 10.1158/1535-7163.MCT-17-0360

Figure 4. Theoretical treatment options for characterized alterations across diverse gastrointestinal cancers.

Figure 4

Abbreviations: FDA = Food and Drug Administration; pts = patients

Excluding variants of unknown significance, the percent breakdown of available treatment options for patients with the most common cancer-types in the cohort. FDA approved agents were prioritized over experimental drugs. Amongst FDA approved agents, on-label drugs were prioritized over off-label drugs. In our population, all of the patients who were candidates for an experimental agent also had targeted FDA-approved drugs available, either on or off-label (see Figure 3).